← Back to Clinical Trials
Recruiting NCT04604444

NCT04604444 Changes in Neuroplasticity Following Intensive Rehabilitation of Aphasia and/or Apraxia of Speech

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04604444
Status Recruiting
Phase
Sponsor Karolinska Institutet
Condition Aphasia
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2017-02-02
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2017-02-02 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The present study aims to investigate the short- and long-term effects of two weeks of intensive speech-language pathology intervention with additional physiotherapy, on aphasia and apraxia of speech (AOS) and their neural correlates in thirty persons with chronic stroke. Changes are studied following intensive treatment of aphasia and AOS with standardised speech-language testing and testing of communication and with voxel-based morphometry (VBM) analysis and resting state functional connectivity (rsFC).

Eligibility Criteria

Inclusion Criteria: * Aphasia 7 months post stroke diagnosed by SLP * Apraxia of Speech 7 months post stroke diagnosed by SLP Exclusion Criteria: * Dementia * Severe loss of sight * Severe loss of hearing * Metal implants (preventing fMRI) * Claustrophobia (preventing fMRI)

Contact & Investigator

Central Contact

Marika J Schütz, Ph.D student

✉ marika.schutz@uu.se

📞 0046737570430

Principal Investigator

Ellika Schalling, Professor

PRINCIPAL INVESTIGATOR

Uppsala University

Frequently Asked Questions

Who can join the NCT04604444 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Aphasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04604444 currently recruiting?

Yes, NCT04604444 is actively recruiting participants. Contact the research team at marika.schutz@uu.se for enrollment information.

Where is the NCT04604444 trial being conducted?

This trial is being conducted at Uppsala, Sweden.

Who is sponsoring the NCT04604444 clinical trial?

NCT04604444 is sponsored by Karolinska Institutet. The principal investigator is Ellika Schalling, Professor at Uppsala University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology